跳至主要内容
临床试验/NCT05384444
NCT05384444进行中(未招募)不适用

Effect of Perioperative Dietary Restriction Strategy on Postoperative Recovery and Outcomes of Patients With Colorectal Cancer : a Multicenter Prospective, Randomized, Controlled Study

Fudan University6 个研究点 分布在 1 个国家目标入组 602 人开始时间: 2022年6月8日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
602
试验地点
6
主要终点
Disease-free Survival

研究概览

简要总结

Extensive preclinical evidence suggests that short-term fasting and fasting mimicking diets (FMDs) can protect healthy cells and render cancer cells more vulnerable to chemotherapy and other therapies. However, fasting is difficult for the old and frail subjects.Therefore, FMDs may be more suitable for postoperative dietary intervention in cancer patients. Colorectal tumors have high glucose consumption, which makes tumor cells very sensitive to changes in nutritional metabolism of the surrounding environment (such as diet restriction / fasting). Previous studies have shown that cyclic FMDs are safe and feasible for cancer patients receiving chemotherapy alone. However, the effects of the FMD in patients under radical surgery for colorectal cancer have not been evaluated so far. This study aims to evaluate the impact of FMDs on postoperative recovery and outcomes of patients with colorectal cancer.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

盲法说明

Allocation concealment:an independent researcher implements the randomized allocation scheme to ensure that the subjects and the researchers who screen the subjects are unable to know the subsequent subjects in advance

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18 ~ 80 years old
  • Patients undergoing radical colorectal cancer resection for the first time
  • Preoperative clinical tumor stage III
  • ASA grade I-III grade
  • With BMI 19-32 kg/m2
  • Adequate liver function, adequate renal function and normal cardiac function
  • Willing to participate in the research of the subject and agree to follow up regularly

排除标准

  • Evidence of distant metastasis before surgery
  • Before surgery, have received treatment of neoadjuvant chemotherapy
  • Type 1 diabetes or intensive insulin therapy
  • Allergies for FMD content
  • Combined with severe primary diseases such as severe immune system or autoimmune system or long-term using of glucocorticoids or immunosuppressant
  • History of opioid abuse, mental illness or cognitive impairment

研究组 & 干预措施

Fasting mimicking diet

Experimental

The cyclic FMD diet consists of a 5 day regimen: day 1 diet of the diet supplies ~1000 kcal (10% protein, 56% fat, 34% carbohydrate), day 2-5 are identical in formulation and provide 800 kcal (9% protein, 44% fat, 47% carbohydrate). At least 4 cyclic FMDs will be performed after operation.

干预措施: Fasting mimicking diet (Other)

regular diet

No Intervention

regular diet

结局指标

主要结局

Disease-free Survival

时间窗: 3 years

DFS is defined as the time from randomisation to the first occurrence of locoregional recurrence, distant metastasis, or death from any cause, whichever occurs first. The data of participants without an event will be censored at the date of the last follow-up. Follow-up of survival will be conducted at least every 3 months beginning at 6 months after surgery. Postoperative recurrence or metastasis will be determined on the basis of imaging studies, endoscopic examination, or histopathological assessment of biopsy specimens, with a review also performed by an expert panel.

次要结局

  • Inflammatory factor level(3 years)
  • heart rate, blood pressure and basal metabolic rate(3 years)
  • body composition(after randomization, before discharge, before and at the completion of each FMD cycle.)
  • Weight, height and BMI(3 years)
  • upper arm circumference and waistline(3 years)
  • plasma protein(3 years)
  • Nutritional status(3 years)
  • Lymphocyte to Monocyte Ratio (LMR)(3 years)
  • Occurrence of clinical complications(3 years)
  • Systemic immune-inflammation index (SII)(3 years)
  • T Lymphocyte cell count(3 years)
  • Feasibility of the FMD in colorectal cancer patients(3 years)
  • Quality of life(QOL)(3 years)
  • Exercise tolerance(3 years)
  • Postoperative pain(3 years)
  • Neutrophil to Lymphocyte Ratio (NLR)(3 years)
  • insulin-like growth factor-I (IGF-I)(3years)
  • insulin(3years)
  • Glucose(3years)
  • Nutritional status score(Dietary intervention phase (up to 4 months) and 6 months after surgery)
  • Quality of life(QOL)(Dietary intervention phase (up to 4 months) and 6 months after surgery)
  • Occurrence of clinical complications(within 2 weeks after each chemotherapy cycle)
  • fasting serum glucose(4 months)
  • fasting insulin(4 months)
  • Overall Survival(3 years)
  • Weight and BMl(Dietary intervention phase (up to 4 months) and 6 months after surgery)
  • upper arm circumference and waist circumference(Dietary intervention phase (up to 4 months) and 6 months after surgery)
  • plasma albumin(Dietary intervention phase (up to 4 months) and 6 months after surgery)
  • Exercise tolerance(Dietary intervention phase (up to 4 months) and 6 months after surgery)
  • insulin-like growth factor 1 (IGF-1)(4 months)
  • C-peptide(4 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Changhong Miao

Director

Fudan University

研究点 (6)

Loading locations...

相似试验

Effect of FMD on Colorectal Cancer Patients | 临床试验